MARKET

ARAV

ARAV

Aravive Inc
NASDAQ
1.320
+0.040
+3.13%
Closed 13:41 11/25 EST
OPEN
1.280
PREV CLOSE
1.280
HIGH
1.360
LOW
1.280
VOLUME
51.44K
TURNOVER
0
52 WEEK HIGH
3.490
52 WEEK LOW
0.5801
MARKET CAP
78.97M
P/E (TTM)
-0.5608
1D
5D
1M
3M
1Y
5Y
Aravive To Participate in Piper’s 34th Annual Healthcare Conference
HOUSTON, Nov. 21, 2022 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a late clinical-stage oncology company developing targeted therapeutics to treat metastatic disease, today announced that Gail McIntyre, Ph.D., DABT, Chief Executive Officer and Rudy ...
GlobeNewswire · 11/21 12:00
Aravive Files Registration Statement for Common Share Resale
Aravive Files Registration Statement for Common Share Resale
MT Newswires · 11/21 04:09
BRIEF-Aravive Inc Files For Resale Of Up To 90.4 Million Shares Of Common Stock By The Selling Stockholders - SEC Filing
Reuters · 11/18 21:50
BRIEF-Aravive Regains Compliance With Nasdaq Minimum Bid Price Requirement
Reuters · 11/16 12:05
Aravive Regains Compliance With Nasdaq's Minimum Bid Price Rule for Continued Listing
Aravive Regains Compliance With Nasdaq's Minimum Bid Price Rule for Continued Listing
MT Newswires · 11/16 10:23
Piper Sandler Maintains Overweight on Aravive, Lowers Price Target to $2
Benzinga · 11/14 11:36
--Piper Sandler Trims Price Target on Aravive to $2 From $6, Keeps Overweight Rating
--Piper Sandler Trims Price Target on Aravive to $2 From $6, Keeps Overweight Rating
MT Newswires · 11/14 07:55
Aravive Q3 EPS $(0.51) Up From $(0.53) YoY, Sales $4.96M Up From $2.41M YoY
Benzinga · 11/10 12:16
More
About ARAV
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. Its lead product candidate, AVB-500, is an ultrahigh-affinity, decoy protein that targets the GAS6-AXL signaling pathway associated with tumor cell growth, tumor metastasis, resistance to treatment, and decreased survival. The Company is evaluating AVB-500 in a registrational Phase III trial in platinum resistant ovarian cancer, a Phase Ib/2 trial in second line plus, clear cell renal cell carcinoma (ccRCC), and a Phase Ib/2 trial in first-line treatment of pancreatic adenocarcinoma. The Company’s lead candidate, Aravive-S6 (AVB-S6)-500, is a GAS6 binding protein and AXL decoy receptor. It is a Fc-fusion protein designed to block the activation of the growth arrest-specific 6 (GAS6)-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL.

Webull offers kinds of Aravive Inc stock information, including NASDAQ:ARAV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ARAV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ARAV stock methods without spending real money on the virtual paper trading platform.